|
業務類別
|
Biotechnology |
|
業務概覽
|
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases. |
| 公司地址
| 1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014 |
| 電話號碼
| +1 702 825-9872 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.zurabio.com |
| 員工數量
| 30 |
| Dr. Kiran Nistala, M.B.B.S.,PhD |
Chief Medical Officer and Head, Development |
美元 409.60K |
23/04/2025 |
| Dr. Sandeep C. Kulkarni, M.D. |
Director and Chief Executive Officer |
-- |
26/01/2026 |
| Ms. Kimberly Ann Davis |
Chief Operating Officer, Secretary and Chief Legal Officer |
美元 437.40K |
26/01/2026 |
| Dr. Gary Whale, PhD |
Chief Technology Officer |
-- |
23/04/2025 |
|
|
| Dr. Ajay Nirula, M.D.,PhD |
Director |
23/02/2026 |
| Dr. Daniel Becker, M.D.,PhD |
Independent Director |
23/05/2025 |
| Dr. Sandeep C. Kulkarni, M.D. |
Director and Chief Executive Officer |
26/01/2026 |
| Mr. Amit D. Munshi |
Chairman of the Board |
23/04/2025 |
| Ms. Jennifer Ann Jarrett |
Independent Director |
23/04/2025 |
| Mr. Steven J. Schoch |
Independent Director |
23/04/2025 |
| Mr. Parvinder Thiara |
Director |
26/01/2026 |
| Dr. Mark Eisner, M.D.,M.P.H. |
Director |
23/02/2026 |
| Dr. Someit Sidhu, M.D. |
Director |
23/04/2025 |
|
|
|
|
